167 related articles for article (PubMed ID: 34452748)
1. Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
Tamura R; Yoshihara K; Matsuo K; Yachida N; Miyoshi A; Takahashi K; Sugino K; Yamaguchi M; Mori Y; Suda K; Ishiguro T; Okuda S; Motoyama T; Nakaoka H; Kikuchi A; Ueda Y; Inoue I; Enomoto T
Gynecol Oncol; 2021 Nov; 163(2):327-333. PubMed ID: 34452748
[TBL] [Abstract][Full Text] [Related]
2. Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
Chen W; Shan B; Zhou S; Yang H; Ye S
BMC Cancer; 2022 Jan; 22(1):92. PubMed ID: 35062908
[TBL] [Abstract][Full Text] [Related]
3. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications.
Chen W; Zhong S; Shan B; Zhou S; Wu X; Yang H; Ye S
J Ovarian Res; 2020 Aug; 13(1):89. PubMed ID: 32771026
[TBL] [Abstract][Full Text] [Related]
4. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer.
Yamada Y; Kawaguchi R; Iwai K; Niiro E; Morioka S; Tanase Y; Kobayashi H
J Obstet Gynaecol; 2020 Jan; 40(1):102-106. PubMed ID: 31335252
[TBL] [Abstract][Full Text] [Related]
5. High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension.
Sakurai M; Satoh T; Matsumoto K; Michikami H; Nakamura Y; Nakao S; Ochi H; Onuki M; Minaguchi T; Yoshikawa H
Int J Gynecol Cancer; 2015 May; 25(4):593-8. PubMed ID: 25756402
[TBL] [Abstract][Full Text] [Related]
6. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Uehara Y; Oda K; Ikeda Y; Koso T; Tsuji S; Yamamoto S; Asada K; Sone K; Kurikawa R; Makii C; Hagiwara O; Tanikawa M; Maeda D; Hasegawa K; Nakagawa S; Wada-Hiraike O; Kawana K; Fukayama M; Fujiwara K; Yano T; Osuga Y; Fujii T; Aburatani H
PLoS One; 2015; 10(6):e0128066. PubMed ID: 26043110
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study.
Bai H; Sha G; Xiao M; Gao H; Cao D; Yang J; Chen J; Wang Y; Zhang Z; Shen K
Oncotarget; 2016 Mar; 7(13):15566-76. PubMed ID: 26863639
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
Man YN; Wang YN; Hao J; Liu X; Liu C; Zhu C; Wu XZ
Int J Gynecol Cancer; 2015 Jan; 25(1):24-32. PubMed ID: 25347092
[TBL] [Abstract][Full Text] [Related]
9. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Tsuchiya A; Sakamoto M; Yasuda J; Chuma M; Ohta T; Ohki M; Yasugi T; Taketani Y; Hirohashi S
Am J Pathol; 2003 Dec; 163(6):2503-12. PubMed ID: 14633622
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
Hirata Y; Murai N; Yanaihara N; Saito M; Saito M; Urashima M; Murakami Y; Matsufuji S; Okamoto A
BMC Cancer; 2014 Nov; 14():799. PubMed ID: 25366985
[TBL] [Abstract][Full Text] [Related]
12. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study.
Ku FC; Wu RC; Yang LY; Tang YH; Chang WY; Yang JE; Wang CC; Jung SM; Lin CT; Chang TC; Chao A; Lai CH
J Formos Med Assoc; 2018 Feb; 117(2):117-125. PubMed ID: 28389144
[TBL] [Abstract][Full Text] [Related]
13. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
[TBL] [Abstract][Full Text] [Related]
14. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
15. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.
Veras E; Mao TL; Ayhan A; Ueda S; Lai H; Hayran M; Shih IeM; Kurman RJ
Am J Surg Pathol; 2009 Jun; 33(6):844-53. PubMed ID: 19342944
[TBL] [Abstract][Full Text] [Related]
16. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
17. Demographic, Clinical, and Prognostic Factors of Ovarian Clear Cell Adenocarcinomas According to Endometriosis Status.
Schnack TH; Høgdall E; Thomsen LN; Høgdall C
Int J Gynecol Cancer; 2017 Nov; 27(9):1804-1812. PubMed ID: 28976447
[TBL] [Abstract][Full Text] [Related]
18. Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
Takaya A; Peng WX; Ishino K; Kudo M; Yamamoto T; Wada R; Takeshita T; Naito Z
Int J Oncol; 2015 Apr; 46(4):1573-81. PubMed ID: 25633807
[TBL] [Abstract][Full Text] [Related]
19. Alternating Amaurosis Fugax in Trousseau Syndrome: A Case Report.
Kunitake K; Inagaki R; Furukawa S; Kitagawa S; Oguchi H; Ito Y
J Stroke Cerebrovasc Dis; 2019 Jul; 28(7):e92-e94. PubMed ID: 31097325
[TBL] [Abstract][Full Text] [Related]
20. Uncommon Human Telomerase Reverse Transcriptase Promoter Mutations Are Associated With Poor Survival in Ovarian Clear Cell Carcinoma.
Nishikimi K; Nakagawa K; Tate S; Matsuoka A; Iwamoto M; Kiyokawa T; Shozu M
Am J Clin Pathol; 2018 Mar; 149(4):352-361. PubMed ID: 29474637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
